Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions

Area of Science:

• Oncology
• Endocrinology
• Cancer Biology

Background:

• Prostate cancer (PCa) is initially androgen-sensitive, with testosterone (T) suppression as standard therapy.
• Castration-resistant prostate cancer (CRPC) can paradoxically respond to T administration.
• Preclinical models show biphasic PCa responses to T: proliferation at low doses, inhibition at high doses.

Purpose of the Study:

• To review preclinical and clinical data on high-dose androgen-induced growth repression in PCa.
• To discuss potential cellular pathways and mechanisms mediating this response.
• To explore clinical applications and identify predictive biomarkers for high-dose T therapy.

Main Methods:

• Review of preclinical studies on androgen biphasic responses in PCa models.
• Analysis of clinical data from patients with advanced PCa treated with high-dose T.
• Discussion of proposed molecular mechanisms and cellular pathways.

Main Results:

• High-dose T administration has shown meaningful clinical responses in some men with PCa.
• Preclinical data consistently demonstrate biphasic dose-dependent effects of T on PCa cells.
• Not all patients respond to high-dose T, indicating variable tumor sensitivity.

Conclusions:

• High-dose T represents a potential therapeutic strategy for advanced prostate cancer, including CRPC.
• Understanding the mechanisms of high-dose T response and resistance is crucial for clinical optimization.
• Identification of predictive biomarkers is essential to guide patient selection for this treatment.